Px-171-004, An Ongoing Open-Label, Phase Ii Study Of Single-Agent Carfilzomib (Cfz) In Patients With Relapsed Or Refractory Myeloma (Mm); Updated Results From The Bortezomib-Treated Cohort
BLOOD（2009）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要